Merck announced the first presentation of results from KEYNOTE-181, a phase III trial investigating Keytruda, an anti-PD-1 therapy, as monotherapy for the second-line treatment of advanced or metastatic esophageal or esophagogastric junction carcinoma.
Array BioPharma Inc. announced updated safety and efficacy results, including mature overall survival, from the safety lead-in of the phase III BEACON CRC trial evaluating the triplet combination of Braftovi (encorafenib), a BRAF inhibitor, Mektovi (binimetinib), a MEK inhibitor and Erbitux (cetuximab), an anti-EGFR antibody, in patients with BRAFV600E-mutant metastatic colorectal cancer.
A global resource that includes data on thousands of inherited variants in the BRCA1 and BRCA2 genes is available to the public. The BRCA Exchange was created through the BRCA Challenge, a long-term demonstration project initiated by the Global Alliance for Genomics and Health to enhance sharing of BRCA1 and BRCA2 data.
The American Society of Clinical Oncology has published standards on the safe handling of hazardous drugs.
A research team led by investigators from the NIH and Global Good has developed a computer algorithm that can analyze digital images of a woman's cervix and accurately identify precancerous changes that require medical attention. This artificial intelligence approach, called automated visual evaluation, has the potential to revolutionize cervical cancer screening, particularly in low-resource settings.
UroGen Pharma Ltd. announced topline results from the ongoing pivotal phase III OLYMPUS clinical trial of UGN-101 (mitomycin gel) for instillation, an investigational mitomycin formulation for the non-surgical treatment of low-grade upper tract urothelial cancer.
A steady, 25-year decline has resulted in a 27% drop in the overall cancer death rate in the United States, translating to approximately 2.6 million fewer cancer deaths between 1991 and 2016. The data come from Cancer Statistics, 2019, the American Cancer Society's widely-quoted annual report on cancer rates and trends.
Patients treated with chemotherapy for most solid tumors during 2000–2014 experienced an increased risk of therapy-related myelodysplastic syndrome/acute myeloid leukemia, a study by NCI researchers shows.
New research from Europe, published in the December 2018 issue of JNCCN—Journal of the National Comprehensive Cancer Network, finds that quality-of-life for people with cancer is reduced by an accumulation of low-level toxicities just as much as it is from high-level adverse events.
Astellas Pharma Inc. and Pfizer Inc. announced that the phase III ARCHES trial evaluating XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC) met its primary endpoint, significantly improving radiographic progression-free survival (rPFS) versus ADT alone. The preliminary safety analysis of the ARCHES trial appears consistent with the safety profile of XTANDI in previous clinical trials in castration-resistant prostate cancer (CRPC). Detailed results will be submitted for presentation at an upcoming medical congress.
